title: LDL-apheresis reduces P-Selectin, CRP and fibrinogen -- possible important implications for improving atherosclerosis.
abstract: Although it is known that LDL-apheresis improves coronary artery stenosis (CAS) as well as ischemic limbs seen in patients with peripheral arterial occlusive disease (PAOD), the underlying mechanisms remain still unknown. LDL-apheresis might exert its favorable action through anti-inflammatory effects. We studied whether or not serum or plasma levels of P-selectin, high sensitivity C-reactive protein (hsCRP), monocyte chemoattractant protein-1 (MCP-1) or fibrinogen could be reduced in patients with PAOD before and after 10 sessions of LDL-apheresis. Sixteen patients (12 patients with hemodialysis, HD) with PAOD were enrolled in the present study. LDL-apheresis was carried out 10 times (treated plasma of 3000 mL) over 5 weeks. Serum levels of P-selectin were significantly reduced from 516 +/- 153 to 290 +/- 52 ng/mL before and after 10-sessions of LDL-apheresis, respectively (P < 0.05). Likewise, serum levels of hsCRP decreased from 9.118 +/- 2.649 to 5.587 +/- 2.445 mg/L (P < 0.01); and plasma fibrinogen levels statistically decreased from 196 +/- 9.82 to 149 +/- 7.97 mg/dL (P < 0.01), whereas serum levels of MCP-1 were not significantly changed. The favorable actions of LDL-apheresis might include anti-inflammatory effects, which could lead to an improvement of CAS and PAOD. Moreover, this intervention might be applicable for patients with atherosclerotic cardiovascular disorders, particularly in patients with HD.
authors.affiliation: Shonan Kamakura General Hospital, Department of Nephrology and Kidney & Dialysis Center, Yamazaki Kamakura, Japan. shuzo@shonankamakura.or.jp
authors.forename: Shuzo
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Machiko
authors.initials: M
authors.lastname: Oka
authors.forename: Hidekazkeu
authors.initials: H
authors.lastname: Moriya
authors.forename: Kyoko
authors.initials: K
authors.lastname: Maesato
authors.forename: Koji
authors.initials: K
authors.lastname: Okamoto
authors.forename: Takayasu
authors.initials: T
authors.lastname: Ohtake
mesh_terms: D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000628:therapy*; D050197:Atherosclerosis / Q000628:therapy*; D015415:Biomarkers / Q000097:blood; D001781:Blood Component Removal / Q000379:methods*; D002097:C-Reactive Protein / Q000032:analysis; D023921:Coronary Stenosis / Q000628:therapy*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood* / Q000302:isolation & purification; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D008077:Lipoproteins, LDL; D019007:P-Selectin; D005340:Fibrinogen; D002097:C-Reactive Protein